Academic Journal
View in EDS

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer.

Bibliographic Details
Title: Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer.
Authors: Janowski EM; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Kole TP; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Chen LN; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Kim JS; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Yung TM; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Collins BT; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Suy S; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Lynch JH; Department of Urology, Georgetown University Hospital , Washington, DC , USA., Dritschilo A; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA., Collins SP; Department of Radiation Medicine, Georgetown University Hospital , Washington, DC , USA.
Source: Frontiers in oncology [Front Oncol] 2015 Jul 03; Vol. 5, pp. 151. Date of Electronic Publication: 2015 Jul 03 (Print Publication: 2015).
Publication Type: Journal Article
Language: English
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Imprint Name(s): Original Publication: [Lausanne : Frontiers Research Foundation]
Abstract: Background: Dysuria following prostate radiation therapy is a common toxicity that adversely affects patients' quality of life and may be difficult to manage.
Methods: Two hundred four patients treated with stereotactic body radiation therapy (SBRT) from 2007 to 2010 for localized prostate carcinoma with a minimum follow-up of 3 years were included in this retrospective review of prospectively collected data. All patients were treated to 35-36.25 Gy in five fractions delivered with robotic SBRT with real time fiducial tracking. Dysuria and other lower urinary tract symptoms were assessed via Question 4b (Pain or burning on urination) of the expanded prostate index composite-26 and the American Urological Association (AUA) Symptom Score at baseline and at routine follow-up.
Results: Two hundred four patients (82 low-, 105 intermediate-, and 17 high-risk according to the D'Amico classification) at a median age of 69 years (range 48-91) received SBRT for their localized prostate cancer with a median follow-up of 47 months. Bother associated with dysuria significantly increased from a baseline of 12% to a maximum of 43% at 1 month (p < 0.0001). There were two distinct peaks of moderate to severe dysuria bother at 1 month and at 6-12 months, with 9% of patients experiencing a late transient dysuria flare. While a low level of dysuria was seen through the first 2 years of follow-up, it returned to below baseline by 2 years (p = 0.91). The median baseline AUA score of 7.5 significantly increased to 11 at 1 month (p < 0.0001) and returned to 7 at 3 months (p = 0.54). Patients with dysuria had a statistically higher AUA score at baseline and at all follow-ups up to 30 months. Dysuria significantly correlated with dose and AUA score on multivariate analysis. Frequency and strain significantly correlated with dysuria on stepwise multivariate analysis.
Conclusion: The rate and severity of dysuria following SBRT is comparable to patients treated with other radiation modalities.
References: CA Cancer J Clin. 2008 Jul-Aug;58(4):196-213. (PMID: 18502900)
Radiat Oncol. 2013 May 13;8:118. (PMID: 23668632)
Urology. 2013 Jan;81(1):56-60. (PMID: 23122544)
J Urol. 2009 Aug;182(2):649-54. (PMID: 19535108)
Int J Radiat Oncol Biol Phys. 2008 Sep 1;72 (1):236-46. (PMID: 18722274)
Radiat Oncol. 2013 Mar 13;8:58. (PMID: 23497695)
Urology. 2000 Dec 20;56(6):899-905. (PMID: 11113727)
Radiat Oncol. 2013 Jan 31;8:30. (PMID: 23369294)
J Urol. 1992 Nov;148(5):1549-57; discussion 1564. (PMID: 1279218)
Urology. 1995 Jan;45(1):87-92. (PMID: 7817484)
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82. (PMID: 21300474)
Cancer. 2011 Oct 1;117(19):4566-72. (PMID: 21412761)
Technol Cancer Res Treat. 2009 Oct;8(5):387-92. (PMID: 19754215)
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):204-12. (PMID: 21167653)
Cancer. 2012 Aug 1;118(15):3681-90. (PMID: 22170628)
J Urol. 2012 Oct;188(4):1151-6. (PMID: 22901567)
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):939-45. (PMID: 24119836)
Urology. 2003 Nov;62(5):786-92. (PMID: 14624895)
Int J Radiat Oncol Biol Phys. 1993 Mar 15;25(4):661-7. (PMID: 8454484)
BMC Urol. 2010 Feb 01;10:1. (PMID: 20122161)
Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4):985-90. (PMID: 8138452)
Med Care. 1996 Mar;34(3):220-33. (PMID: 8628042)
Urology. 2006 Jul;68(1):166-71. (PMID: 16844457)
Radiother Oncol. 2013 Nov;109(2):217-21. (PMID: 24060175)
Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):563-6. (PMID: 10524406)
Radiat Oncol. 2011 Jan 10;6:3. (PMID: 21219625)
Radiother Oncol. 2003 Feb;66(2):159-65. (PMID: 12648787)
N Engl J Med. 2008 Mar 20;358(12):1250-61. (PMID: 18354103)
Front Oncol. 2011 Dec 08;1:48. (PMID: 22655248)
Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):979-85. (PMID: 12605976)
Semin Radiat Oncol. 2008 Jan;18(1):41-7. (PMID: 18082587)
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. (PMID: 24399786)
J Clin Oncol. 1991 Feb;9(2):328-34. (PMID: 1988579)
J Urol. 2005 Aug;174(2):646-50; discussion 650. (PMID: 16006930)
Med Care. 2003 May;41(5):582-92. (PMID: 12719681)
BJU Int. 2005 Mar;95(4):597-602. (PMID: 15705087)
Nurs Health Sci. 2011 Mar;13(1):27-33. (PMID: 21352429)
J Urol. 2006 Aug;176(2):593-6; discussion 596. (PMID: 16813895)
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):83-9. (PMID: 17855010)
Radiat Oncol. 2012 Jun 09;7:82. (PMID: 22681643)
Front Oncol. 2014 Oct 21;4:290. (PMID: 25374844)
Cancer. 2007 Jun 1;109(11):2239-47. (PMID: 17455209)
Grant Information: P30 CA051008 United States CA NCI NIH HHS
Contributed Indexing: Keywords: AUA; CyberKnife; dysuria; expanded prostate index composite; prostate cancer; quality of life; stereotactic body radiation therapy
Entry Date(s): Date Created: 20150721 Date Completed: 20150720 Latest Revision: 20200930
Update Code: 20260130
PubMed Central ID: PMC4490223
DOI: 10.3389/fonc.2015.00151
PMID: 26191507
Database: MEDLINE
Description
ISSN:2234-943X
DOI:10.3389/fonc.2015.00151